Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain
Journal of Comparative Effectiveness Research · 2025
DOI: 10.57264/cer-2024-0116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Ruth Álvarez Cabellos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Virgen de la Salud University Hospital, Avda. De Barber, 30, 45005, Toledo, Spain. Hauptthemen laut MEDLINE: Cetuximab, Head and Neck Neoplasms, Antineoplastic Agents, Immunological, Chemoradiotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
To estimate the cost–effectiveness of cetuximab in combination with radiotherapy compared with radiotherapy alone, for the treatment of locally advanced head and neck cancer patients in Spain.
Methods
A probabilistic Markov model (second-order Monte Carlo simulation) with a five-year time horizon and quarterly Markov cycles was performed from the perspective of the Spanish National Health System (NHS).
Results
The additional cost and quality-adjusted life-year (QALY) gain per patient receiving radiotherapy in combination with cetuximab compared with radiotherapy alone was €4356 (95% CI: €4350–4362) and 0.2380 (95% CI: 0.2370–0.2391) QALY, respectively. The incremental cost per QALY gain was €18,303 (95% CI: €18,243–18,354) with a probability of cost–effectiveness of 65.4% for a willingness to pay of €30,000 per QALY gained.
Conclusion
According to the results of this analysis, the addition of cetuximab to radiotherapy would be a cost-effective alternative to radiotherapy alone in the treatment of locally advanced head and neck cancer in Spain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, Virgen de la Salud University Hospital, Avda. De Barber, 30, 45005, Toledo, Spain.
- Radiation Oncology Department, Cruces University Hospital/Instituto de Investigación Biobizkaia, Pza. Cruces, s/n, 48903, Baracaldo, Spain.
- Parc Taulí University Hospital, Pharmacy Department, Parc Taulí 1, 08208, Sabadell, Spain.
- Merck, SLU, C/María de Molina, 40, 28006, Madrid, Spain, an affiliate of Merck KGaA.
- Health Value, HE Department, C/Virgen de Aránzazu, 21, 28034, Madrid, Spain.
Zitieren
APA
Cabellos, R. Á., Cacicedo, J., Capafons, S. R., Los Santos Real, H., Julián, M. B., Rubio-Rodríguez, D., & Rubio-Terrés, C. (2025). Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0116
Vancouver
Cabellos RÁ, Cacicedo J, Capafons SR, Los Santos Real H, Julián MB, Rubio-Rodríguez D, et al. Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2024-0116
BibTeX
@article{Cabellos2025,
author = {Cabellos, Ruth Álvarez and Cacicedo, Jon and Capafons, Susana Redondo and Los Santos Real, Heidi De and Julián, Miriam Brines and Rubio-Rodríguez, Darío and Rubio-Terrés, Carlos},
title = {Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain},
journal = {Journal of Comparative Effectiveness Research},
year = {2025},
doi = {10.57264/cer-2024-0116}
}
EUVIMED